Actio Biosciences Secures $66M Series B to Accelerate Precision Medicine Breakthroughs

Actio Biosciences, Inc. is excited to announce a significant milestone in our journey toward transforming how treatments are developed and delivered.

We have successfully raised $66,000,000 in funding, a pivotal achievement that underscores the confidence investors have in our innovative approach to precision medicine and genetics.

At Actio Biosciences, our mission is to harness scientific breakthroughs to develop therapeutics that target shared, underlying biological mechanisms across a range of rare and common diseases.

This fresh infusion of capital will accelerate our ambitious research and development efforts by enabling us to expand our focus on identifying high-potential drug discovery programs where both biological and technical risks are minimized.

By leveraging our deep expertise in genetics, drug discovery, and data sciences, we are uniquely positioned to streamline the typically arduous drug development process and deliver exceptionally potent and precisely targeted therapeutics to patients in need.

The commitment from our investors not only validates our strategy but also empowers us to invest in cutting-edge technology, forge strategic collaborations, and recruit additional industry talents to bolster our research capabilities.

This financial milestone will further fuel our pursuit of new therapeutic candidates, ensuring that we remain at the forefront of developing meaningful medicines from one breakthrough to many.

As we move forward with renewed vigor and expanded resources, Actio Biosciences is more dedicated than ever to advancing precision medicine and making a lasting impact on global health.

The future holds immense promise, and we are proud to be leading the charge toward a new era in medical innovation.